Both Moderna and AstraZeneca have used cutting-edge designs to reduce their vaccines’ development time.
Rigor académico, oficio periodístico
Artículos sobre Vaccines
Mostrando 461 - 480 de 780 artículos
A group of 28 vaccine researchers said we might have a vaccine by late-2021, though it could take until well into 2022.
From 2017 to 2019, Twitter users in the United States saw many tweets related to vaccination but only rarely encountered anti-vaccine content and almost never saw content from bots.
The history of anti-vaccination theories can help us understand how such claims capture a popular following. The same misinformation used against 19th century smallpox vaccine is still in use today.
Australians who refuse vaccines spend a lot of time trying to understand vaccine choices and think they’re making evidence-based decisions.
The way we deliver vaccines continues to evolve. Here’s a look at needle-free vaccine technologies from history to the modern day.
Medical innovation is often accelerated in a time of crisis.
A pediatrician answers parents’ questions about catching up on missed childhood vaccinations and why that’s so important.
An unprecedented level of research has gone into understanding the novel coronavirus. Here’s what we still don’t know.
Australia’s contribution to the global COVAX initiative helps secure future vaccines. Here’s the full field of candidates.
Public trust is key to a successful immunisation programme.
A sports management scholar weighs in on the potential consequences of holding Big Ten football games in the fall instead of waiting for a vaccine or better safety procedures.
Several vaccines are in Phase 3 trials. So when will we know whether any of these will protect against COVID-19?
There’s a targeted subunit protein vaccine, an mRNA vaccine, and a needle-free DNA vaccine. Here’s what that all means.
Researchers rarely report what’s in a placebo.
Will a vaccine for COVID-19 be safe? Animal testing, human clinical trials and post-approval surveillance give us good grounds to believe that a future approved vaccine will work and be safe.
The cold supply chain keeps vaccines fresh during distribution, but the current system is nowhere near large enough to distribute the billions of COVID-19 vaccines that the world needs.
A bioethicist explains a recent report that recommends how to distribute a COVID-19 vaccine equitably.
Governments must embrace policies that promote sharing and collective invention to create and distribute a vaccine quickly.
Wearing face masks may allow a tiny number of viral particles to slip through, possibly allowing our body to gain some sort of immunity.
Principales colaboradores
-
Professorial Fellow, University of Canberra
-
Vice-Chancellor's Research Fellow, School of Health and Biomedical Sciences, RMIT University
-
Professor of Medicine, University of Virginia
-
Research associate, Warren Alpert Medical School, Brown University, Brown University
-
Professor of Immunology, Vice-Chancellors Distinguished Professorial Fellow, Head of Immunology and Translational Research, Victoria University
-
Lecturer in Virology, Queen's University Belfast
-
Professor of Microbiology, School of Medicine, University of Washington
-
Associate Professor of Biology, Rochester Institute of Technology
-
Dean Faculty of Health Sciences and Professor of Vaccinology at University of the Witwatersrand; and Director of the SAMRC Vaccines and Infectious Diseases Analytics Research Unit, University of the Witwatersrand
-
Associate Professor and ARC Future Fellow, The University of Western Australia
-
Professor, Discipline of Paediatrics and Child Health, University of Sydney
-
Assistant Professor of Political Science, Oklahoma State University
-
Professor of Immunology, RMIT University
-
Senior Lecturer; MD, Victoria University
-
Associate Professor, Discipline of Childhood and Adolescent Health, University of Sydney
